Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,435.37
(
-0.88%
)
US TECH 100
28,468.60
(
-1.12%
)
Dow Jones
49,624.95
(
-0.88%
)
Brent Oil
106.33
(
2.06%
)
Bitcoin
79,210.51
(
-2.28%
)
News Focus
News Focus
Post# of 257575
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122986
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 145237

Friday, 09/07/2012 10:27:26 AM

Friday, September 07, 2012 10:27:26 AM

Post# of 257575
JNJ resubmits Xarelto NDA in PCI sub-indication of ACS:

http://finance.yahoo.com/news/janssen-research-development-submits-complete-120000837.html

This NDA, which is separate from the rejected Xarelto NDA in ACS per se, was voluntarily withdrawn by JNJ in July 2012 (#msg-77346396). In today’s PR, JNJ confirms that the additional information in the resubmission for PCI is in response to questions raised by the FDA in the June CRL rejecting the NDA in ACS (#msg-76856261).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today